[CLSTR]
< Back to situations

We’ll email you as it develops, and you can follow the whole thread from day one.

[SITUATION] · [ACTIVE]

6 clusters · 32 sources · 24 days · First seen · Last updated

Categories: HEALTH

Advancements in Alzheimer's blood tests and drug safety

Entities: Roche Diagnostics · Therapeutic Goods Administration · National Institute on Aging · U.S. Department of Veterans Affairs · Alzheimer's Association

Overview

Research into Alzheimer's biomarkers continues to evolve, with recent findings refining the utility of blood-based testing. While plasma p-tau217 remains a key indicator—showing healthy older adults a one-in-three chance of memory impairment within five years and nearly 80% within ten—studies suggest its predictive power in symptom-free individuals is moderate (AUC = 0.67) compared to its high accuracy during the clinical stage. In contrast, biomarkers reflecting amyloid-β protein misfolding have shown higher predictive ability in the preclinical phase (AUC = 0.79), and combining such markers with genetic and demographic data can yield high predictive accuracy (AUC = 0.87). Additionally, an NIH-funded study identified a set of 34 circulating RNAs (circRNAs) that may outperform p-tau217 in forecasting symptom onset two to four years in advance.

Clinical implementation is advancing in Australia, where the Therapeutic Goods Administration has approved a rapid blood test. Launched at the Asia-Pacific Centre of Excellence for Alzheimer’s Diagnosis in Sydney, this Roche Diagnostics assay measures pTau181, pTau217, and the ApoE4 genetic risk factor, delivering results in approximately 18 minutes. The test offers a less invasive alternative to PET scans or lumbar punctures and is expected to be available via specialist referral within six to nine months, with potential Medicare coverage by year-end.

Regarding treatment, a real-world study by Duke Health involving over 230 patients found that the FDA-approved drug lecanemab's safety and efficacy align with clinical trials. While 24.3% of participants experienced Amyloid Related Imaging Abnormalities (ARIA), most side effects resolved without hospitalization under close monitoring.

Timeline

  1. 1 day ago

    [HEALTH] 2 sources
    Alzheimer's disease research shows progress in drug safety and early detection

    New studies highlight advancements in Alzheimer's care, including the real-world safety of lecanemab and the ability of p-tau217 blood tests to predict disease onset up to a decade before symptoms appear.

  2. 7 days ago

    [HEALTH] 5 sources
    Alzheimer’s blood tests advance with biomarkers and Sydney rollout

    Researchers found blood circRNA markers that better predict Alzheimer’s symptom onset, while Australia introduced an 18‑minute blood test for early diagnosis, using Roche’s pTau and ApoE4 assays.

  3. 11 days ago

    [HEALTH] 2 sources
    Alzheimer biomarker P‑tau 217 shows limited predictive power in preclinical stage

    German research finds P‑tau 217 strong only after clinical onset, while an amyloid‑β misfolding marker predicts Alzheimer’s earlier; a combined panel reaches AUC 0.87.

  4. 11 days ago

    [HEALTH] 5 sources
    Australia greenlights rapid Alzheimer’s blood test

    Australia’s TGA approved a rapid blood test detecting Alzheimer’s biomarkers with ~90 % accuracy, promising earlier diagnosis and treatment planning for millions of sufferers.

  5. 16 days ago

    [HEALTH] 3 sources
    Simple Blood Test Predicts Dementia Risk, Researchers Report

    Blood‑based p‑tau217 testing may flag higher dementia risk, while worldwide lifestyle trials and upcoming WHO guidelines aim to curb a projected rise to 153 million cases by 2050.

  6. 25 days ago

    [HEALTH] 15 sources
    Blood Test Using p‑tau217 Biomarker Predicts Alzheimer’s Risk Up to a Decade

    A study of 2,684 older adults shows a blood test for p‑tau217 can predict Alzheimer’s risk up to 10 years; high levels signal 38% five‑year and 78% ten‑year risk, though the test isn’t yet for routine use.

Sources

7news.com.au · abc17news.com · abc7ny.com · agedcareinsite.com.au · alsnewstoday.com · analytica-world.com · bionity.com · businessnews.lk · capital.gr · clinicalomics.com · eldiariony.com · epochtimes.com · greekherald.com.au · index.hu · it-boltwise.de · kion546.com · knowridge.com · kvia.com · montaze-skal.cz · mymotherlode.com · naukawpolsce.pap.pl · newsbomb.gr · newshealth.biz · newswise.com · nlcafe.hu · podcasts.dk · postandcourier.com · theatlantavoice.com · thenightly.com.au · ui42.sk · whec.com · womensagenda.com.au

This summary has been updated 3 times: see revision history